What is she best known for?
The fields of study she is best known for:
- Cancer
- Internal medicine
- Breast cancer
Her primary scientific interests are in Breast cancer, Internal medicine, Oncology, Surgery and Cancer.
Her work carried out in the field of Breast cancer brings together such families of science as Stage and Prospective cohort study.
Her studies in Oncology integrate themes in fields like Trastuzumab, Survival rate, Young adult, Metastasis and Mastectomy.
Elizabeth A. Mittendorf has included themes like Vitamin D and neurology, Acosog z0011 and Risk factor in her Surgery study.
The concepts of her Cancer study are interwoven with issues in Immunology and Bioinformatics.
Her Sentinel lymph node study incorporates themes from Carcinoma, Dissection and Axilla.
Her most cited work include:
- Glypican-1 identifies cancer exosomes and detects early pancreatic cancer (1299 citations)
- Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer: The ACOSOG Z1071 (Alliance) Clinical Trial (685 citations)
- PD-L1 Expression in Triple-Negative Breast Cancer (528 citations)
What are the main themes of her work throughout her whole career to date?
Elizabeth A. Mittendorf focuses on Breast cancer, Internal medicine, Oncology, Cancer and Chemotherapy.
Elizabeth A. Mittendorf combines subjects such as Stage, Surgery, Clinical trial and Immunology with her study of Breast cancer.
Her work on Prospective cohort study as part of general Surgery research is frequently linked to In patient, thereby connecting diverse disciplines of science.
Her work in Oncology addresses issues such as Mastectomy, which are connected to fields such as Radiation therapy and Retrospective cohort study.
Her Cancer research includes themes of Gastroenterology and Proportional hazards model.
Her work deals with themes such as Biopsy, Dissection, Lymph and Axilla, which intersect with Sentinel lymph node.
She most often published in these fields:
- Breast cancer (69.60%)
- Internal medicine (61.60%)
- Oncology (56.40%)
What were the highlights of her more recent work (between 2019-2021)?
- Breast cancer (69.60%)
- Internal medicine (61.60%)
- Oncology (56.40%)
In recent papers she was focusing on the following fields of study:
Elizabeth A. Mittendorf mainly investigates Breast cancer, Internal medicine, Oncology, Triple-negative breast cancer and Cancer.
The various areas that she examines in her Breast cancer study include Cancer research, Surgical oncology and Immunotherapy.
Her research in Cancer research tackles topics such as Immune system which are related to areas like Monoclonal antibody.
Her study in Oncology is interdisciplinary in nature, drawing from both Pembrolizumab, Clinical trial, Phases of clinical research, Metastatic breast cancer and Randomized controlled trial.
In her study, which falls under the umbrella issue of Triple-negative breast cancer, Cyclophosphamide and Stromal tumor is strongly linked to Neoadjuvant therapy.
Her work on Axillary Lymph Node Dissection and Sentinel lymph node as part of general Cancer research is frequently linked to Context, bridging the gap between disciplines.
Between 2019 and 2021, her most popular works were:
- Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. (47 citations)
- Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant. (43 citations)
- Tumor mutational burden and PTEN alterations as molecular correlates of response to PD-1/L1 blockade in metastatic triple-negative breast cancer (26 citations)
In her most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Breast cancer
Her main research concerns Breast cancer, Internal medicine, Oncology, Chemotherapy and Triple-negative breast cancer.
Her Breast cancer research is under the purview of Cancer.
Her studies deal with areas such as Regimen and PTEN as well as Cancer.
Her Oncology research incorporates themes from Clinical trial, Metastatic breast cancer, Randomized controlled trial and Disease, Nodal disease.
Her work investigates the relationship between Chemotherapy and topics such as Neoadjuvant therapy that intersect with problems in Germline.
Her Triple-negative breast cancer study combines topics from a wide range of disciplines, such as Cancer research, Atezolizumab, Immune system and Median follow-up.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
